Zaleplon: Price, Dosage & Where to Buy

Zaleplon is a sedative-hypnotic medicine used mainly for the short-term treatment of insomnia, particularly difficulty falling asleep. It is a prescription medicine in the United Kingdom and is available as a generic capsule. Zaleplon belongs to the hypnotic group of medicines, although its pharmacological classification is not otherwise specified on the label.

Zaleplon is a sedative-hypnotic medicine that acts on calming signalling pathways in the brain. These pathways involve gamma-aminobutyric acid, commonly called GABA, which reduces activity in the central nervous system. By strengthening this calming effect, zaleplon can promote sleepiness and help reduce the time needed to fall asleep.

Its action begins relatively quickly, which is why the label associates its use with bedtime. The same central nervous system effects can also cause drowsiness, reduced alertness, dizziness, impaired coordination, memory problems or other changes in thinking and behaviour. Alcohol, opioids and other medicines that depress the central nervous system can add to these effects.

Zaleplon is indicated for the short-term treatment of insomnia. It is used when the main difficulty is falling asleep, and controlled clinical studies showed that it can reduce the time needed to fall asleep during short-term treatment. The label does not show that zaleplon increases total sleep time or reduces the number of awakenings.

Sleep disturbance can sometimes be associated with an underlying physical or psychiatric condition, so persistent or worsening insomnia needs medical assessment. New thinking or behaviour changes during treatment also require prompt evaluation. Zaleplon is intended for short-term use rather than ongoing treatment without review.

The label lists 5 mg and 10 mg oral capsules. The usual starting dose is 10 mg for most non-elderly adults. The label lists 5 mg as potentially sufficient for certain low weight individuals.

The label lists 20 mg as a dose that may be considered occasionally when a lower dose has not helped, while doses above 20 mg are not recommended. The label lists 5 mg for elderly or debilitated patients, and doses over 10 mg are not recommended for these patients. The label lists 5 mg for mild to moderate hepatic impairment and states that use is not recommended in severe hepatic impairment.

The label lists no dose adjustment for mild to moderate renal impairment, while severe renal impairment has not been adequately studied. The label lists an initial dose of 5 mg when cimetidine is being used at the same time. The label describes administration immediately before bedtime or after difficulty falling asleep in bed, with a full night of sleep recommended.

Store at 20° to 25°C, protected from light, in a tight, light-resistant container as defined in the USP/NF. Keep the capsules in their labelled container and away from children. Follow the label directions to maintain quality.

A missed dose means the planned bedtime dose was not taken. Because zaleplon acts quickly and is associated with next-day impairment when insufficient sleep remains, a missed dose should not be replaced by an extra dose or taken when there is not enough time for a full night of sleep.

A pharmacist or prescriber can advise about the individual situation, particularly if missed doses occur repeatedly or treatment is being stopped. Rapid dose reduction or abrupt discontinuation can cause withdrawal-like symptoms.

The label states that there are no studies of zaleplon in pregnant women and that zaleplon is not recommended during pregnancy. Animal studies did not show teratogenicity at the doses examined, but effects on offspring viability, growth and development were observed in some rat studies.

A doctor or pharmacist should be consulted before use during pregnancy or when planning a pregnancy. The label also describes exposure through lactation in animal studies, so breastfeeding requires individual medical advice.